The companies — and others — are testing similar approaches against lung, breast and pancreatic cancers.

At an interim data check, investigators of a key trial found the individualized mRNA treatment kept disease from returning and stopped its spread, sparking a surge in Moderna…

Pharmaceutical companies Merck, known as MSD outside the United States and Canada, and Moderna announced on Wednesday that their individualized neoantigen therapy, intismeran…

Risultati promettenti dallo studio di fase 3: il vaccino personalizzato mRNA riduce il rischio di recidiva del melanoma.